Skip to main content

Table 3 Grade 3–4 treatment-emergent adverse events (AEs) reported in ≥2% of patients

From: A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

 

Safety population (N = 199)

Hematologic AEs, n (%)

 

  Anemia

52 (26.1)

  Neutropenia

50 (25.1)

  Thrombocytopenia

29 (14.6)

  Leukopenia

19 (9.5)

Non-hematologic AEs, n (%)

 

  Pneumonia

26 (13.1)

  Upper respiratory tract infection

8 (4.0)

  Fatigue

8 (4.0)

  Hypokalemia

14 (7.0)

  Hyperglycemia

5 (2.5)

  Hypocalcemia

5 (2.5)

Investigations

 

  Neutrophil count decreased

17 (8.5)

  Platelet count decreased

14 (7.0)

  White blood cell count decreased

14 (7.0)

Discontinuation due to AEs, n (%)

18 (9.0)